Vol. 1, Issue 2, Part A (2019)

Coronary artery disease (CAD) is leading due to disability and death of the working population, and successful its treatment is largely determined by maintaining adequate coronary blood flow, including through interventions, percutaneous interventions. This article describes the efficacy of the adding herbal hepatoprotector - Hepofresh 2 tablets 3 times a day on the framework of the standard therapy on some indicators of the functional state of the liver of patients with coronary heart disease with stable angina of III-IV FC, subjected to percutaneous intervention (PCI). And the results show that Hepofresh contributes to better tolerance of treatment, increases its effectiveness and prevent the development of side effects and various liver disorders in patients CAD after PCI.